Home > Division of Cancer RNA Research
Division of Cancer RNA Research
- Apr. 1, 2025
- Akihide Yoshimi’s project titled 'Verification of drug discovery targeting cancer-specific cell surface receptors' has been selected for the AMED FY2025 Drug Discovery Booster.
- Apr. 1, 2025
- Akihide Yoshimi has been appointed as a Collaborative Professor at the Graduate School of Medicine, the University of Tokyo.
- Apr. 1, 2025
- Parihe Muhetaer joined our team as a researcher!
- Apr. 1, 2025
- Kenshiro Nishihara joined our team as a researcher!
- Apr. 1, 2025
- Nanami Yamano joined our team as an observership visitor!
- Apr. 1, 2025
- Sakura Inoue joined our team as an observership visitor!
- Apr. 1, 2025
- Lu Zhu joined our team as an observership visitor!
- Mar. 20, 2025
- The case report authored by Takuya Izumi has been accepted and is now in press in Annals of Hematology!
- Mar. 18, 2025
- Akihide Yoshimi’s project titled 'Establishment of Efficient Design Techniques for Splicing-Regulatory Nucleic Acid Therapeutics Using the hareCLIP Method' has been selected for the AMED FY2025 Drug
- Mar. 18, 2025
- Akihide Yoshimi’s project titled 'Identification and Validation of Drug Targets for Multiple Diseases and Conditions through the Development of a Novel Transcriptome Analysis Platform' has been selected for the AMED FY2025 Drug Discovery Infrastructure Advancement Research Program.

Our Research Interest
Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.

(Figure was made by using Wordle based on our recent papers)